Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone in Recurrent or Metastatic Urothelial Carcinoma (UTRUST)
NCT05895864Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in urothelial carcinoma (UC), sponsored by Sun Yat-sen Memorial Hospital. Started Jun 2023; status: recruiting.
02
Drugs
utidelone
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05895864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895864.